NCT03864627

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	MOR106	MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
DRUG	Placebo	Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).

Timeline

• Start date: 2019-03-25
• Primary completion: 2020-02-27
• Completion: 2020-02-27
• First posted: 2019-03-06
• Last updated: 2021-01-05
• Results posted: 2021-01-05

Locations

14 sites across 1 country: United States

Regulatory

• FDA-regulated drug study